Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Recruiting2
Active Not Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT05983159Phase 2Recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

NCT03994796Phase 2Active Not Recruiting

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT06239467Phase 1Recruiting

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT05571670TerminatedPrimary

Bile Acids in Acute Insulin Resistance

Showing all 4 trials

Research Network

Activity Timeline